Latest Industry Insights

In this piece, Adam Clore explores how smart automation can help synthetic biology companies become more resilient.

The science and medicine worlds are experiencing a new revolution, and this time the protagonist is the mRNA molecule. In this article, we explore why bioplatforms support this revolution.

PerkinElmer announced the launch of a new automated gas chromatography, the GC 2400 Platform. We spoke to Suneet Chadha to learn more about this latest introduction.

Delix Therapeutics is developing non-hallucinogenic psychedelics for use as at-home medications for mental health conditions. To find out more, we spoke to the CEO, Mark Rus.

Beckley Psytech recently announced that they have dosed the first healthy volunteers in their Phase I trial of an intranasally delivered formulation of 5-MeO-DMT, named BPL-003. To find out more about their trial approach and wider research into 5-MeO-DMT, we spoke to Beckley’s chief scientific offer, Dr. Steve Wooding.

Technology Networks learns about the "unusual" spread of the monkeypox virus in non-endemic countries, possible vaccination strategies against the virus and if there are effective treatments available.

Blackrock Neurotech, a leader in brain-computer interface (BCI) device design, recently has announced a collaboration with Venice, CA-based software developer AE Studio. To find out more, we spoke to Evan Coopersmith, AE Studio’s executive vice-president of data science.

Technology Networks learns about serum epitope repertoire analysis and some of the applications it could benefit, including cancer diagnostics and COVID-19 studies.

We spoke to Neil Torbett, PhD, CEO of PhoreMost to learn more about “undruggable” targets and how the SITESEEKER® platform can identify these novel sites in the human proteome.

To find out more about how early-stage funding could improve longevity research, we had the pleasure of speaking to Garri Zmudze, executive director of the Longevity Science Foundation.